Mené en Allemagne sur 29 patients atteints d'une leucémie aiguë, cet essai randomisé évalue l'efficacité d'un entraînement à base d'exercices d'endurance et de résistance, pour développer leurs capacités physiques et améliorer leur qualité de vie pendant une chimiothérapie d'induction

Endurance and resistance training in patients with acute leukemia undergoing induction chemotherapy—a randomized pilot study

Wehrle, Anja ; Kneis, Sarah ; Dickhuth, Hans-Hermann ; Gollhofer, Albert ; Bertz, Hartmut

Purpose : Acute leukemia (AL) and its initial treatment can impair physical functioning and capacity significantly. Exercise as a countermeasure has been investigated in few studies confirming its feasibility and safety during intensive induction chemotherapy, but the relative effects of diverse exercise programs have not been analyzed. Therefore, we aimed to investigate independent effects of endurance and resistance training on physical capacity and quality of life (QOL). Methods : [...]

Mené sur des patients atteints d'un carcinome à cellules rénales à haut risque, cet essai randomisé évalue la toxicité, les effets indésirables sur la qualité de vie auto-déclarée, du sunitinib dispensé en traitement adjuvant

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

Staehler, M. ; Motzer, R. J. ; George, D. J. ; Pandha, H. S. ; Donskov, F. ; Escudier, B. ; Pantuck, A. J. ; Patel, A. ; DeAnnuntis, L. ; Bhattacharyya, H. ; Ramaswamy, K. ; Zanotti, G. ; Lin, X. ; Lechuga, M. ; Serfass, L. ; Paty, J. ; Ravaud, A.

Background : Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy (hazard ratio 0.76; 95% confidence interval, 0.59–0.98; two-sided P=0.03). We report safety, therapy management, and patient-reported outcomes for patients receiving sunitinib and placebo in the S-TRAC trial. Patients and methods : Patients were stratified by the University of California, Los Angeles Integrated Staging [...]

Menée en France par questionnaire auprès de 84 patientes atteintes d'un cancer du sein et âgées entre 20 et 35 ans, cette étude analyse l'impact de la maladie et des traitements, 6 mois après le diagnostic, sur la qualité de leur vie sexuelle

Sexual quality of life evaluation after treatment among women with breast cancer under 35 years old

Blouet, Anaïse ; Zinger, Marie ; Capitain, Olivier ; Landry, Sébastien ; Bourgeois, Hugues ; Seegers, Valérie Thepot ; Pointreau, Yoann

Purpose : To qualify the quality of patients sexual lives after treatment among women with breast cancer under 35 years old and compare results to the literature. Methods : Sexual quality of life was measured for 84 women aged 20 to 35 years old at diagnosis, with two validated quality of sexual life questionnaires, Brief Index of Sexual Functioning for Women (BISF-W) and Female Sexual Function Index (FSFI), at least six months after breast cancer diagnosis. Two other questionnaires were used [...]

Mené sur des patientes atteintes d'un cancer du sein de stade avancé et porteuses d'une mutation BRCA, cet essai de phase III compare l'intérêt, du point de vue de la qualité de vie déclarée par les patientes, du talazoparib, un inhibiteur de PARP dispensé par voie orale, et d'une chimiothérapie de type PCT choisie par le médecin (doublet de chimiothérapie à base de sels de platine)

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Ettl, J. ; Quek, R. G. W. ; Lee, K. H. ; Rugo, H. S. ; Hurvitz, S. ; Goncalves, A. ; Fehrenbacher, L. ; Yerushalmi, R. ; Mina, L. A. ; Martín, M. ; Roché, H. ; Im, Y. H. ; Markova, D. ; Bhattacharyya, H. ; Hannah, A. L. ; Eiermann, W. ; Blum, J. L. ; Litton, J. K.

Background : In the EMBRACA phase III trial, talazoparib (1 mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician’s choice of chemotherapy (PCT; capecitabine, eribulin, gemcitabine, or vinorelbine) in patients with HER2-negative advanced breast cancer carrying a germline BRCA1/2 mutation; we evaluated patient-reported outcomes (PROs). Patients and methods : Patients were randomized 2 : 1 to receive talazoparib or PCT. PROs were assessed at day 1 [...]

Menée en Corée à partir de données portant sur 61 patientes atteintes d'un cancer du sein de stade I à III, cette étude de cohorte prospective analyse le risque d'alopécie permanente induite par une chimiothérapie (durée de suivi : 3 ans)

Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study

Kang, Danbee ; Kim, Im‐Ryung ; Choi, Eun‐Kyung ; Im, Young Hyuck ; Park, Yeon Hee ; Ahn, Jin Seok ; Lee, Jeong Eon ; Nam, Seok Jin ; Lee, Hae Kwang ; Park, Ji‐Hye ; Lee, Dong‐Youn ; Lacouture, Mario E. ; Guallar, Eliseo ; Cho, Juhee

Background : Although chemotherapy‐induced alopecia (CIA) is considered temporary, some patients report persistent alopecia several years after chemotherapy. There is, however, a paucity of long‐term prospective data on the incidence and impact of permanent CIA (PCIA). The objective of our study was to estimate the long‐term incidence of PCIA in a cohort of patients with breast cancer whose hair volume and density were measured prior to chemotherapy and who were followed for 3 years after [...]

Cette étude présente, pour 40 pays européens en 2018, des projections d'incidence de cancer et de mortalité spécifique pour 25 types de cancers

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

Ferlay, J. ; Colombet, M. ; Soerjomataram, I. ; Dyba, T. ; Randi, G. ; Bettio, M. ; Gavin, A. ; Visser, O. ; Bray, F.

Introduction : Europe contains 9% of the world population but has a 25% share of the global cancer burden. Up-to-date cancer statistics in Europe are key to cancer planning. Cancer incidence and mortality estimates for 25 major cancers are presented for the 40 countries in the four United Nations-defined areas of Europe and for Europe and the European Union (EU-28) for 2018. Methods : Estimates of national incidence and mortality rates for 2018 were based on statistical models applied to the [...]

A partir des données du registre écossais des cancers colorectaux incluant 1 939 patients, et menée à l'échelle du génome, cette étude identifie des polymorphismes à simple nucléotide non synonymes en association avec la survie

Genome-wide scan of the effect of common nsSNPs on colorectal cancer survival outcome

Theodoratou, Evropi ; Farrington, Susan M. ; Timofeeva, Maria ; Din, Farhat V. N. ; Svinti, Victoria ; Tenesa, Albert ; Liu, Tao ; Lindblom, Annika ; Gallinger, steven ; Campbell, Harry ; Dunlop, Malcolm G.

Background : We conducted a genome-wide scan to identify non-synonymous SNPs (nsSNPs) that might influence survival after a diagnosis of colorectal cancer (CRC). Methods : We genotyped 7679 nsSNPs in 1939 Scottish patients from the Scottish Colorectal Cancer Study recruited soon after a CRC diagnosis and prospectively followed for survival outcomes. All-cause and CRC-specific survival analyses were conducted using Cox proportional hazard models adjusted for stage, age and sex for all cancer [...]

A partir de données portant sur 483 patientes atteintes d'un cancer du sein de novo de stade IV HER2+ diagnostiqué entre 1998 et 2015, cette étude rétrospective analyse l'efficacité sur le long terme, du point de vue de la survie sans progression et de la survie globale, des thérapies ciblées (trastuzumab, pertuzumab), en combinaison ou non avec des traitements localisés

Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy

Wong, Yao ; Raghavendra, Akshara Singareeka ; Hatzis, Christos ; Irizarry, Javier Perez ; Vega, Teresita ; Horowitz, Nina ; Barcenas, Carlos H. ; Chavez‐MacGregor, Mariana ; Valero, Vicente ; Tripathy, Debu ; Pusztai, Lajos ; Murthy, Rashmi K.

An increasing proportion of human epidermal growth receptor 2 (HER2) positive (HER2+) metastatic breast cancer (MBC) is diagnosed as de novo stage IV disease. We hypothesize that a subset of these patients who achieve no evidence of disease (NED) status after multimodality HER2‐targeted treatments may have prolonged progression‐free survival (PFS) and overall survival (OS).Patients with de novo stage IV, HER2+ MBC (n = 483) diagnosed between 1998 and 2015 were identified at two institutions [...]

Menée aux Etats-Unis à partir de données portant sur 306 patients adultes ayant survécu à une tumeur du système nerveux central pendant l'enfance (âge médian : 25,3 ans), cette étude analyse leur autonomie et leurs capacités fonctionnelles et sociales en lien avec les traitements anticancéreux reçus

Attainment of Functional and Social Independence in Adult Survivors of Pediatric CNS Tumors: A Report From the St Jude Lifetime Cohort Study

Tara M. Brinkman ; Kirsten K. Ness ; Zhenghong Li ; I-Chan Huang ; Kevin R. Krull ; Amar Gajjar ; Thomas E. Merchant ; James L. Klosky ; Robyn E. Partin ; Ingrid Tonning Olsson ; Frederick Boop ; Paul Klimo Jr ; Wassim Chemaitilly ; Raja B. Khan ; Deokumar Srivastava ; Leslie L. Robison ; Melissa M. Hudson ; Gregory T. Armstrong

Purpose : Beyond survival, achieving independence is a primary goal for adult survivors of pediatric CNS tumors. However, the prevalence of and risk factors for failure to achieve independence, assessed with multiple concurrent indicators, have not been examined. Patients and Methods : Functional and social independence was assessed in 306 survivors (astrocytoma [n = 130], medulloblastoma [n = 77], ependymoma [n = 36], and other [n = 63]; median current age, 25.3 years [range, 18.9 to 53.1 [...]

Menée aux Etats-Unis à partir de données portant sur 1 832 patients ayant survécu à un cancer de la thyroïde diagnostiqué avant l'âge de 50 ans et sur 7 921 témoins, cette étude analyse le risque de complications gynécologiques et d'événements indésirables liés à la reproduction, en lien avec les traitements anticancéreux reçus

Reproductive and gynecological complication risks among thyroid cancer survivors

Blackburn, Brenna E. ; Ganz, Patricia A. ; Rowe, Kerry ; Snyder, John ; Wan, Yuan ; Deshmukh, Vikrant ; Newman, Michael ; Fraser, Alison ; Smith, Ken ; Herget, Kimberley ; Kim, Jaewhan ; Kirchhoff, Anne C. ; Porucznik, Christina ; Hanson, Heidi ; Abraham, Dev ; Monroe, Marcus ; Hashibe, Mia

Purpose : Thyroid cancer is the most rapidly increasing cancer in the USA, affects a young, mostly female population, and has high survival. The aim of this study was to determine if there is an increased risk of reproductive system adverse events or pregnancy complications among women diagnosed with thyroid cancer under the age of 50. Methods : Up to five female cancer-free individuals were matched to each female thyroid cancer survivor diagnosed before the age of 50 based on birth year, birth [...]

Menée à partir de données portant sur 2 638 patients atteints d'un cancer papillaire de la thyroïde (623 hommes, 2 015 femmes ; âge médian : 46 ans), cette étude rétrospective évalue l'association entre la présence de la mutation BRAF V600E et la mortalité spécifique, chez les hommes

BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer

Fei Wang ; Shihua Zhao ; Xiaopei Shen ; Guangwu Zhu ; Rengyun Liu ; David Viola ; Rossella Elisei ; Efisio Puxeddu ; Laura Fugazzola ; Carla Colombo ; Barbara Jarzab ; Agnieszka Czarniecka ; Alfred K. Lam ; Caterina Mian ; Federica Vianello ; Linwah Yip ; Garcilaso Riesco-Eizaguirre ; Pilar Santisteban ; Christine J. O’Neill ; Mark S. Sywak ; Roderick Clifton-Bligh ; Bela Bendlova ; Vlasta Sýkorová ; Yangang Wang ; Mingzhao Xing

Purpose : To test whether the prognostic risk of male sex in papillary thyroid cancer (PTC) is determined by BRAF V600E and can thus be stratified by BRAF status. Patients and Methods : We retrospectively investigated the relationship between male sex and clinicopathologic outcomes in PTC, particularly mortality, with respect to BRAF status in 2,638 patients (male, n = 623; female, n = 2,015) from 11 centers in six countries, with median age of 46 years (interquartile range, 35-58 years) at [...]

A partir d'une revue systématique de la littérature (24 études), cette étude analyse les symptômes psychosociaux (dépression, anxiété) d'enfants et d'adolescents ayant perdu un membre de leur famille décédé de cancer

Psychosocial outcomes in cancer-bereaved children and adolescents – A systematic review

Hoffmann, Rahel ; Kaiser, Julia ; Kersting, Anette

Objective : Due to the unique importance of parental and sibling relationships and concurrently existing developmental challenges, the loss of a parent or sibling due to cancer is a highly stressful event for children and adolescents. This is the first systematic review that integrates findings on psychosocial outcomes after parental or sibling cancer bereavement. Methods : A systematic search of Web of Science, PubMed, PsycINFO, and PubPsych was conducted, last in December 2017. Quantitative [...]

Menée aux Etats-Unis auprès de patients atteints d'un cancer de stade avancé, cette étude prospective évalue l'association entre une utilisation de médicaments anti-dépresseurs, des symptômes dépressifs et la durée du séjour à l'hôpital

Use of Antidepressant Medications Moderates the Relationship Between Depressive Symptoms and Hospital Length of Stay in Patients with Advanced Cancer

Wong, Risa L. ; El‐Jawahri, Areej ; D'Arpino, Sara M. ; Fuh, Charn‐Xin ; Johnson, P. Connor ; Lage, Daniel E. ; Irwin, Kelly E. ; Pirl, William F. ; Traeger, Lara ; Cashavelly, Barbara J. ; Jackson, Vicki A. ; Greer, Joseph A. ; Ryan, David P. ; Hochberg, Ephraim P. ; Temel, Jennifer S. ; Nipp, Ryan D.

Among patients with cancer, depressive symptoms are associated with worse clinical outcomes, including greater health care utilization. As use of antidepressant medications can improve depressive symptoms, we sought to examine relationships among depressive symptoms, antidepressant medications, and hospital length of stay (LOS) in patients with advanced cancer.From September 2014 to May 2016, we prospectively enrolled patients with advanced cancer who had an unplanned hospitalization. We [...]

Menée en Allemagne auprès de 136 patients atteints d'un mélanome malin de stade IA, cette étude analyse les facteurs associés à leur peur de la progresssion de la maladie, et évalue l'effet de cette peur sur leur qualité de vie

Fear of cancer progression in patients with stage IA malignant melanoma

Wagner, Tobias ; Augustin, Matthias ; Blome, Christine ; Forschner, Andrea ; Garbe, Claus ; Gutzmer, Ralf ; Hauschild, Axel ; Heinzerling, Lucie ; Livingstone, Elisabeth ; Loquai, Carmen ; Schadendorf, Dirk ; Terheyden, Patrick ; Mueller-Brenne, Tina ; Kähler, Katharina C.

We aimed to determine the prevalence and importance of fear of cancer progression (FoP) in melanoma patients with stage IA tumours to assess psychosocial and demographic factors associated with severity of FoP and to determine the relationship of FoP and quality of life (QoL). One hundred and thirty-six patients with stage IA melanoma completed the short version of the Fear of Progression Questionnaire (FoP-Q-SF), the Hospital Anxiety and Depression Scale (HADS) and the EORTC-QLQ-C30. We found [...]

A partir d'une revue systématique de la littérature publiée entre 1980 et 2018 (20 études), cette étude analyse les facteurs associés à la santé mentale et à la qualité de vie auto-déclarée, chez des patients pédiatriques ayant survécu à une tumeur cérébrale

A systematic review of factors related to children's quality of life and mental health after brain tumor

Bell, Hayley ; Ownsworth, Tamara ; Lloyd, Owen ; Sheeran, Nicola ; Chambers, Suzanne

Purpose : Brain tumor has been found to have a major impact on children's quality of life (QOL); yet, the subjective impact of the illness is still not well understood. This review aimed to investigate factors related to children's subjective well‐being (SWB), or self‐reported QOL and mental health after brain tumor. A further aim was to determine the consistency between child and parent‐proxy ratings of children's SWB and common factors associated with both child and parent‐proxy ratings. [...]

Menée dans un contexte britannique et américain, cette étude analyse le rapport coût-efficacité du pembrolizumab en traitement de première ligne chez des patients atteints d'un cancer du poumon non à petites cellules de stade avancé

Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer

Georgieva, Mina ; da Silveira Nogueira Lima, Joao P. ; Aguiar, Pedro, Jr. ; de Lima Lopes, Gilberto, Jr. ; Haaland, Benjamin

Background : Anti-PD-1 immunotherapy has dramatically shifted therapeutic perspectives for advanced non-small cell lung cancer (NSCLC). We assessed cost-effectiveness of anti-PD-1 antibody pembrolizumab compared to platinum-doublet chemotherapy as first-line therapy for advanced NSCLC. Methods : We retrieved survival, progression, and safety data comparing first-line pembrolizumab to platinum-doublets for advanced NSCLC patients with PD-L1 expression ≥50%, non-mutated EGFR, and non-translocated [...]

Menée aux Etats-Unis auprès de 100 patients âgés de plus de 60 ans et atteints d'une leucémie myéloïde aiguë, et auprès de 11 oncologues, cette étude longitudinale analyse les discordances dans leurs perceptions relatives au pronostic et aux risques et bénéfices des chimiothérapies

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia

El‐Jawahri, Areej ; Nelson‐Lowe, Margaret ; VanDusen, Harry ; Traeger, Lara ; Abel, Gregory A. ; Greer, Joseph A. ; Fathi, Amir ; Steensma, David P. ; LeBlanc, Thomas W. ; Li, Zhigang ; DeAngelo, Daniel ; Wadleigh, Martha ; Hobbs, Gabriela ; Foster, Julia ; Brunner, Andrew ; Amrein, Philip ; Stone, Richard M. ; Temel, Jennifer S.

Older patients (≥60 years) with acute myeloid leukemia (AML) face difficult decisions regarding treatment with “intensive” chemotherapy that carries significant toxicity for a small chance of a cure versus “nonintensive” chemotherapy to control the disease, but with fewer side effects. However, studies of how these patients understand the risks and benefits of such treatments are lacking.We conducted a longitudinal study of older patients newly diagnosed with AML assessing patients’ (n = 100) [...]

Menée aux Pays-Bas par entretiens auprès de 26 oncologues, cette étude analyse les enjeux associés à la demande d'un second avis médical par les patients, notamment en termes de communication entre le médecin et son patient et de coûts financiers et logistiques pour le système de santé

Assessment of challenges encountered by Dutch oncologists when patients ask for second opinions

Hillen, M. A. ; Woei, A. Jin F. H. ; Smets, E. A. ; van Maarschalkerweerd, P. A. ; van Laarhoven, H. M. ; Sommeijer, D. W.

Many patients with cancer seek second opinions to reconfirm their diagnosis, acquire more information, or receive better treatment.1 The desirability of a high rate of second opinions has been much debated. Proponents stress potential health gains, improved acceptance of initial diagnosis, and reduced anxiety for patients.2 Critics emphasize the limited clinical value,3 potential treatment delays, and financial and logistical burdens for the health care system.4 The triadic nature of [...]